Infinity Pharmaceuticals announced data from its Phase 2 study of retaspimycin hydrochloride in combination with docetaxel in patients with non-small cell lung cancer (NSCLC) who had a history of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback